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Summary	
Background	
Data from EUROCARE have consistently shown lower survival for adolescents and young adults 
(AYAs; aged 15–24 years) than for children (0–14 years) for most cancers that affect both groups, 
and modest survival improvements up to 2000–02. AYAs have longer survival than that of adults 
for most cancers. We used the latest definition of AYAs (aged 15–39 years) and provided estimates 
of 5-year relative survival for European AYAs with cancer diagnosed in 2000–07, compared with 
children and adults (40–69 years) with cancer, and assessed survival improvements over time. 
Methods	
We analysed data from population-based cancer registries of 27 European countries participating in 
EUROCARE-5. We used the so-called complete method to estimate 5-year, population-weighted 
relative survival for 19 cancers affecting AYAs and children, and for 27 cancers affecting AYAs 
and adults. We assessed relative-survival differences between children versus AYAs, and between 
AYAs versus adults, using the Z test. We used the period approach to estimate 5-year relative 
survival over time for children and AYAs, and used a generalised linear model to model survival 
time trends (1999–2007) and to assess the significance of changes over time. 
Findings	
We analysed 56 505 cancer diagnoses in children, 312 483 in AYAs, and 3 567 383 in adults. For 
all cancers combined, survival improved over time for AYAs (from 79% [95% CI 78·1–80·5] in 
1999–2002 to 82% [81·1–83·3] in 2005–07; p<0·0001) and children (from 76% [74·7–77·1] to 
79% [77·2–79·4]; p<0·0001). Survival improved significantly in children and AYAs for acute 
lymphoid leukaemia (p<0·0001) and non-Hodgkin lymphoma (p<0·0001 in AYAs and p=0·023 in 
children). Survival improved significantly in AYAs only for CNS tumours (p=0·0046), 
astrocytomas (p=0·040), and malignant melanomas (p<0·0001). Survival remained significantly 
worse in AYAs than in children for eight important cancers: acute lymphoid leukaemias, acute 
myeloid leukaemias, Hodgkin's lymphomas, non-Hodgkin lymphomas, astrocytomas, Ewing's 
sarcomas, and rhabdomyosarcomas (p<0·0001 in all cases), and osteosarcomas (p=0·011). 
Interpretation	
Notwithstanding the encouraging results for some cancers, and overall, we showed poorer survival 
in AYAs than in children for the eight important cancers. Recent European initiatives to improve 
outcomes in AYAs might reduce the survival gap between children and AYAs, but this reduction 
can only be verified by future population-based studies. 
Funding	
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Introduction	
No internationally agreed definition exists for adolescents and young adults (AYAs) for cancer 
purposes; age ranges of 15–24 years and 15–29 years (at cancer diagnosis) have been used. 
EUROCARE1 has shown that AYAs (aged 15–24 years) have poorer survival than children (aged 
0–14 years) for most cancers that affect both groups, and survival improvements up to 2000–02 
were modest. Additionally, AYAs (aged 15–29 years) have better survival than adults for most 
cancers.2 Poorer survival in AYAs than in children has been attributed to various factors including 
no or few clinical trials conducted in AYAs, the dearth of specific treatment guidelines, differences 
in cancer biology, variations in the pharmacokinetics of chemotherapeutic agents, and delays in 
diagnosis and treatment.3, 4, 5, 6, 7 AYAs with cancer are, in many ways, neglected by both 
paediatric and adult oncologists, yet effective disease management necessitates a multiprofessional 
approach incorporating expertise from both specialties.8 To improve cancer outcomes for AYAs, 
various initiatives—including promoting collaboration between paediatric and adult oncologists, 
developing national policies for managing AYAs with cancer, and setting up specific treatment 
units—have been implemented in several European countries8 and worldwide.9 
In the present EUROCARE-5 study, we used the latest definition of AYAs (age 15–39 years) 
proposed by the US National Cancer Institute10 and accepted by the European Network for Cancer 
in Children and Adolescents (ENCCA) to provide population-based analyses of 5-year relative 
survival for European AYAs with cancer, compared with survival in children (aged 0–14 years) and 
adults (aged 40–69 years). We also present time trends in 5-year relative survival for cancers 
typically occurring in AYAs and children, to assess whether survival improvements in the older age 
group still lag behind those in children. The time period of our analyses pre-dates implementation of 
the European initiatives to improve outcomes for AYAs, and thus provides an important baseline 
from which to assess the effectiveness of these initiatives. 
Research in context 
Evidence before this study 
There is no internationally agreed definition of adolescents and young adults (AYAs) for cancer 
purposes; age ranges of 15–24 years and 15–29 years (at cancer diagnosis) have been used. The US 
National Cancer Institute proposed defining AYAs as those aged 15–39 years at diagnosis. The 
European Network for Cancer in Children and Adolescents has adopted this definition and is 
promoting its use in Europe. Less is known about factors that affect cancer incidence, outcomes, 
and quality of life in AYAs than other age groups. Furthermore AYAs with cancer have not had the 
same mortality reduction seen in recent years in younger and older patients with cancer (for some 
cancers). To try to improve outcomes for AYAs with cancer, various initiatives—including the 
promotion of collaboration between paediatric and adult oncologists, development of national 
policies for managing AYAs with cancer, and setting up of AYA-specific treatment units—have 
been implemented in several European countries. Over the past 5 years population-based analyses 
of incidence and outcomes for AYAs with cancer have been completed in France, the Netherlands, 
and the UK. However, the latest survival analysis for Europe as a whole was provided by 
EUROCARE-4 for patients aged 15–24 years who were diagnosed in 1995–2002. 
Added value of this study 
The present EUROCARE-5 study provides the latest population-based, 5-year relative survival 
estimates for European AYAs (aged 15–39 years at diagnosis) compared with children (0–14 years) 
and adults (40–69 years), diagnosed with cancer in 2000–07. The study also provides survival time 
trends (1999–2007) for AYAs and children, and assesses whether survival improvements in AYAs 
still lag behind those in children; and, for the first time to our knowledge, analyses survival 
differences between AYAs and adults. We found that survival improved during the study period for 
both AYAs and children with cancer in Europe, and that survival improvements were similar in 
both these age categories. This finding contrasts with previous results that AYAs lag behind 
children in terms of survival improvement. However, survival remained significantly worse in 
AYAs than in children for acute lymphoid leukaemia, acute myeloid leukaemia, Hodgkin's 
lymphoma, non-Hodgkin lymphoma, astrocytoma, Ewing's sarcoma of bone, rhabdomyosarcoma, 
and osteosarcoma; and for acute myeloid leukaemia, soft-tissue sarcomas, and fibrosarcomas, 
survival remained unchanged for AYAs over the study period. These findings are in line with data 
from earlier time periods (1995–2002). 
Implications of all the available evidence 
AYAs have worse survival than children for many cancers affecting both groups, justifying 
initiatives to improve outcomes for adolescents and young adults. For cancers affecting AYAs and 
children, it has been suggested that AYAs should be treated in an integrated paediatric–adult 
multidisciplinary setting. This integration would increase the likelihood of inclusion in clinical 
trails, and improve family and social support. For AYAs with acute lymphoid leukaemia, data 
clearly indicate that although tumour biology is relatively unfavourable in this group, application of 
paediatric treatment protocols is feasibile and improves outcomes. However, robust evidence that 
regimens used to treat children actually benefit AYAs is only available for acute lymphoid 
leukaemia. Thus, further studies are needed to understand why survival improvements in AYAs lag 
behind those in children for many important cancers affecting both. The time of these analyses 
(patients diagnosed in 2000–07, and followed up until at least the end of 2008) pre-dates 
implementation of European initiatives to improve outcomes, and thus provides important baseline 
data to evaluate whether initiatives will lead to improved survival in European AYAs with cancer. 
Methods	
Study	design	and	data	collection	
We used data provided by European population-based cancer registries participating in 
EUROCARE-5.11 Registries provided information on the site and morphology of each cancer 
diagnosed, which was coded according to the International Classification of Disease for Oncology 
third revision (ICD-O-3).12 Data for AYAs and for adults were provided by 97 of the 99 cancer 
registries contributing to the EUROCARE-5 adult database.13 
Data for cancers in children were supplied by 72 of the 74 cancer registries contributing to the 
EUROCARE-5 childhood database.14 These registries were the same as those that provided data for 
AYA and adult cancers for 21 of 27 countries (Finland, Iceland, Norway, Sweden, Ireland, 
Northern Ireland, Scotland, Austria, Belgium, Netherlands, Switzerland, Croatia, Malta, Portugal, 
Slovenia, Bulgaria, Estonia, Latvia, Lithuania, Poland, and Slovakia). For the remaining six 
countries (England, France, Germany, Italy, Spain, and Wales), data from specialised childhood 
registries were used instead, which were generally national (in one case supranational, the England 
and Wales childhood cancer registry) rather than the several subnational registries used for adult 
cancers, maximising population coverage. Preliminary analysis showed that childhood survival 
results were the same irrespective of whether data from specialised or general registries were used. 
Table 1 shows the population coverage of cancer registration (children and adults) in each of the 27 
countries in this study. 
Table 1. Cancer cases in adolescents (aged 15–19 years) and young adults (20–39 years) diagnosed 
in 2000–07, in 27 European countries, with data quality indicators 
 
2000–07 
2000–03 
lost to 
follow‐
up* 
Percentage of 
population covered by 
cancer registration (%) 
Included in 
time trend 
analysis 
 
Age 
15–19 
years 
Age 20–
39 years 
Death 
certificate 
only or by 
autopsy 
cases† 
Major 
errors 
Patients 
included 
in analysis
Microscopically 
verified 
Unspecified 
cases‡   
Adult 
database 
Childhood 
database   
Finland  565 
(8∙3%) 
6276 
(91∙7%)  28 (0∙4%)  5 (0∙1%)  6808  6756 (99∙2%)  160 (2∙4%)  17 (0∙5%) 100%  100%  Yes 
Iceland  59 
(9∙8%) 
540 
(90∙2%)  2 (0∙3%)  0  596  592 (99∙3%)  7 (1∙2%)  0  100%  100%  Yes 
Norway  446 
(5∙6%) 
7574 
(94∙4%)  17 (0∙2%) 
72 
(0∙9%)  7930  7850 (99∙0%)  115 (1∙5%)  29 (0∙8%) 100%  100%  Yes 
Sweden  661 
(5∙6%) 
11 228 
(94∙4%)  20 (0∙2%) 
18 
(0∙2%)  11 848  11 806 (99∙6%)  295 (2∙5%)  50 (0∙9%) 100%  100%  Yes 
England  4522 
(5∙6%) 
75 787 
(94∙4%)  378 (0∙5%) 
522 
(0∙6%)  79 409  76 007 (95∙7%)  2445 (3∙1%)
240 
(0∙6%)  100%  100%
§  Yes 
Ireland  507 
(7∙3%) 
6392 
(92∙7%)  16 (0∙2%) 
47 
(0∙7%)  6836  6709 (98∙1%)  217 (3∙2%)  0  100%  100%  Yes 
Northern 
Ireland 
466 
(5∙6%) 
7861 
(94∙4%)  16 (0∙2%) 
16 
(0∙2%)  8294  8200 (98∙9%)  141 (1∙7%)  6 (0∙1%)  100%  100%  Yes 
Scotland  287 
(6∙6%) 
4064 
(93∙4%)  14 (0∙3%) 
2 
(0∙05%)  4335  3723 (85∙9%)  222 (5∙1%)  0  100%  100%  Yes 
Wales  169 
(6∙0%) 
2638 
(94∙0%)  7 (0∙2%) 
61 
(2∙2%)  2739  2622 (95∙7%)  162 (5∙9%)  0  100%  100%
§  Yes 
Austria  786 
(6∙0%) 
12 250 
(94∙0%)  166 (1∙3%) 
60 
(0∙5%)  12 810  12 698 (99∙1%)  342 (2∙7%)  0  100%  100%  Yes 
Belgium  652 
(6∙2%) 
9942 
(93∙8%)  0  0  10 189  9961 (97∙8%)  276 (2∙7%)  0  58%  56%  No 
France  606 
(6∙9%) 
8230 
(93∙1%)  0 
12 
(0∙1%)  8590  8520 (99∙2%)  118 (1∙4%) 
137 
(2∙2%)  23%  100%
§  No 
 
2000–07 
2000–03 
lost to 
follow‐
up* 
Percentage of 
population covered by 
cancer registration (%) 
Included in 
time trend 
analysis 
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only or by 
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cases‡   
Adult 
database 
Childhood 
database   
Germany  1610 
(5∙8%) 
25 959 
(94∙2%)  417 (1∙5%) 
30 
(0∙1%)  27 034  26 497 (98∙0%)  620 (2∙3%) 
402 
(3∙0%)  23%  100%
§  Yes¶ 
Netherlands  1577 
(5∙4%) 
27 524 
(94∙6%)  17 (0∙1%)  0  29 083  28 894 (99∙4%)  279 (1∙0%) 
241 
(1∙7%)  100%  100%  Yes 
Switzerland  247 
(6∙2%) 
3714 
(93∙8%)  8 (0∙2%)  7 (0∙2%)  3881  3867 (99∙6%)  33 (0∙9%) 
185 
(9∙7%)  30%  29%  Yes
¶ 
Croatia  490 
(6∙6%) 
6921 
(93∙4%)  40 (0∙5%)  6 (0∙1%)  7365  6202 (84∙2%) 
1351 
(18∙3%)  0  100%  100%  No 
Italy  1514 
(4∙8%) 
30 050 
(95∙2%)  49 (0∙2%) 
84 
(0∙3%)  31 389  29 719 (94∙7%)  2158 (6∙9%)
409 
(2∙3%)  35%  36%
§  Yes¶ 
Malta  52 
(9∙6%) 
488 
(90∙4%)  2 (0∙4%)  5 (0∙9%)  524  505 (96∙4%)  14 (2∙7%)  0  100%  100%  Yes 
Portugal  585 
(5∙5%) 
10 125 
(94∙5%)  0 
66 
(0∙6%)  10 461  10 257 (98∙0%)  373 (3∙6%)  70 (1∙1%) 76%  70%  No 
Slovenia  196 
(5∙6%) 
3311 
(94∙4%)  6 (0∙2%)  0  3501  3487 (99∙6%)  40 (1∙1%)  0  100%  100%  Yes 
Spain  393 
(5∙3%) 
7007 
(94∙7%)  42 (0∙6%) 
2 
(0∙03%)  7234  7111 (98∙3%)  203 (2∙8%)  59 (1∙1%) 17%  34%
§  Yes¶ 
Bulgaria  576 
(5∙3%) 
10 291 
(94∙7%)  335 (3∙1%)  7 (0∙1%)  10 525  10 081 (95∙8%)  641 (6∙1%)  25 (0∙5%) 100%  100%  Yes 
Estonia  140 
(8∙1%) 
1591 
(91∙9%)  10 (0∙6%)  3 (0∙2%)  1716  1678 (97∙8%)  62 (3∙6%)  5 (0∙6%)  100%  100%  Yes 
Latvia  229 
(8∙5%) 
2475 
(91∙5%)  100 (3∙7%) 
39 
(1∙4%)  2565  2408 (93∙9%)  276 (10∙8%) 0  100%  100%  No 
Lithuania  294 
(6∙9%) 
3967 
(93∙1%)  43 (1∙0%) 
10 
(0∙2%)  4193  4030 (96∙1%)  367 (8∙8%)  39 (1∙7%) 100%  100%  Yes 
Poland  540 
(9∙1%) 
5374 
(90∙9%)  25 (0∙4%) 
86 
(1∙5%)  5760  4883 (84∙8%)  889 (15∙4%) 77 (2∙7%) 13%  12%  Yes
¶ 
Slovakia  552 
(7∙8%) 
6499 
(92∙2%)  181 (2∙6%) 
2 
(0∙03%)  6868  6549 (95∙4%)  202 (2∙9%)  0  100%  100%  Yes 
Data are n (%) and n, unless otherwise stated. Also shown are the percentages of the country 
populations covered by the adult and childhood databases, and the countries included in the survival 
time-trend analyses. Major errors include missing or invalid data items. 
* 
Proportion of patients diagnosed in 2000–03 and lost to follow-up (alive with less than 5 
years of follow-up); for the French registries this quality indicator was calculated for cases 
diagnosed in 2000–02. 
† 
Data for death certificate only cases unavailable for Sweden, Belgium, France, Netherlands, 
and Portugal because death certificate information is not used to initiate cancer registration. 
‡ 
Consisting the following International Classification of Childhood Cancers third edition 
diagnostic groups: Ie, IIe, IIIf, VIc, VIIc, VIIIe, IXe, Xe, and XIIb. 
§ 
Specialised childhood cancer registry. 
¶ 
Registries in countries without 100% population coverage but uninterrupted data from 1995 
to 2007, and included in the time-trend analyses are: in Germany (Hamburg and Saarland), 
in Switzerland (Basel, Geneva, Grisons, St Gallen, and Valais), in Italy (Biella, Ferrara, 
Friuli Venezia Giulia, Liguria Mesothelioma, Latina, Modena, Napoli, Parma, Ragusa, 
Reggio Emilia, Romagna, Sassari, Torino, Trentino, Umbria), in Spain (Girona), and in 
Poland (Cracow, Kielce, and Silesia). 
 
All primary malignant cancers were included in the analyses, except non-melanoma skin cancers 
and pilocytic astrocytoma. Pilocytic astrocytoma is the most common CNS neoplasm in children 
but it was excluded because it has a borderline ICD-O-3 behaviour code. Non-melanoma skin 
cancers were excluded because cancer registry data on these cancers is generally incomplete. If two 
or more cancers were diagnosed in a patient, all were included thus we estimated survival for a 
particular cancer diagnosis and not a particular individual. Cancers were grouped into 46 diagnostic 
categories: 19 non-carcinoma categories (affecting AYAs and children) and 27 carcinoma 
categories (affecting AYAs and adults), as defined by the International Classification of Childhood 
Cancers third edition (ICCC-3;15appendix p 1). 
Statistical	analysis	
We estimated 5-year relative survival for cancers diagnosed in children, AYAs, and adults, in 27 
European countries in 2000–07, who were followed up until at least Dec 31, 2008. Relative survival 
is the ratio of observed survival in patients with cancer to expected survival for individuals in the 
general population matched by age, sex, and time period. We estimated expected survival by the 
Ederer II method.16 Relative survival is an estimate of cancer-specific survival because it removes 
the effect of mortality due to competing causes, which can vary widely between countries. We used 
the so-called complete method to estimate 5-year relative survival.17 This method is similar to the 
established cohort method,16 but also includes the most recently diagnosed patients (in this study, 
those diagnosed in 2004–07) who do not have 5 years of follow-up. 
To provide valid estimates of European survival we applied population weightings to region-
specific relative survival estimates to correct for differing numbers of children, AYAs, and adults in 
the five different regions of Europe (northern [Finland, Iceland, Norway, and Sweden], central 
[Austria, Belgium, France, Germany, Netherlands, and Switzerland], southern [Croatia, Italy, 
Malta, Portugal, Slovenia, and Spain], and eastern Europe [Bulgaria, Estonia, Latvia, Lithuania, 
Poland, and Slovakia], and the UK and Ireland [England, Ireland, Northern Ireland, Scotland, and 
Wales]). For cancers in patients aged 0–39 years at diagnosis, the weightings applied to relative 
survival estimates for each European region consisted of the ratio of the population of that age in 
the region in 2000–07, to that of the European population of the same age in the same period. For 
adults aged 40–69 years with cancer, the weightings were derived from the entire adult population 
(those aged 15–99 years) of each European region and Europe as a whole.13 
We compared 5-year relative survival between children (0–14 years) and adolescents (15–19 years); 
between children and young adults (20–39 years); between children and AYAs; and between AYAs 
and adults. The significance of survival differences was assessed by the Z test, assuming as null 
hypothesis that differences between each pair of relative survival estimates were normally 
distributed with zero mean, and that the variance was given by the sum of the corresponding 
variances. P values less than 0·05 were considered to be significant. 
To assess changes in 5-year relative survival from 1999 to 2007 we used only cancer registries 
providing uninterrupted data from at least 1995 to 2007. 43 registries were identified with 
uninterrupted data for AYAs (table 1), and 41 of 43 registries previously identified by Gatta and 
colleagues14 were used that had uninterrupted data for children (except the registries of Hungary 
and Denmark). To provide reliable predictions for recently diagnosed patients, we estimated 5-year 
relative survival using the period approach.17, 18 We defined three periods: patients in follow-up in 
1999–2001 (diagnosed during 1995–2001); patients in follow-up in 2002–04 (diagnosed during 
1998–2004); and patients in follow-up in 2005–07 (diagnosed during 2001–07). For these three 
periods, the last year of follow-up and last year of diagnosis do not coincide exactly; for example, 
the period estimate for 2005–07 includes follow-up information in 2008 and incidence data up to 
2007.19 
For cancers that did not seem to have a linear change in relative survival with time we tested 
linearity, by comparing a model assuming linear change with time with a model in which time 
changed quadratically. We then used the likelihood ratio test to compare the two models and hence 
exclude a non-linear change in relative survival over time (appendix p 3). 
We present time trends in 5-year relative survival for children, adolescents, young adults, and 
AYAs, for all cancers combined and for the major diagnostic groups whose survival changed 
significantly during the study period. For all cancers combined, survival was casemix-adjusted by 
multiplying the relative survival of each diagnostic category with weightings proportional to the 
corresponding numbers of cases in children, adolescents, young adults, and AYAs, and adding 
together these figures. Diagnostic categories that contributed to combined survival of all cancers 
were acute lymphoid leukaemias, acute myeloid leukaemia, Hodgkin's lymphoma, non-Hodgkin 
lymphoma, CNS and miscellaneous intracranial and intraspinal neoplasms, osteosarcomas, 
chondrosarcomas, Ewing's sarcoma, soft-tissue sarcomas, germ-cell tumours, melanoma, and 
carcinomas of thyroid, breast, colorectum, appendix, male genital tract, female genital tract, urinary 
tract, head and neck, liver, lung and trachea (appendix p 1), and other cancers as a single group (all 
cancers in the databases that do not fit into the 19 diagnostic categories of cancers affecting both 
children and AYAs, or the 27 carcinomas affecting both AYAs and adults). 
To obtain mean yearly changes in mortality for 1999–2007, for Europe as a whole, we modelled 
relative survival using a generalised linear model. We assumed that the number of reported deaths 
in each time interval, calculated as the sum of the excepted deaths in the general population and the 
excess deaths due to cancer, followed a Poisson distribution. The model included sex, 5-year age 
groups, and country as categorical variables and time of follow-up and year of diagnosis as 
continuous variables. Diagnostic category was only included as covariate in the model for all 
cancers combined. A separate model was fitted to each diagnostic category and to each age group 
(ie, children, adolescents, young adults, and AYAs). The probability of the relative excess risk of 
death not being one was assessed by the two-tailed Wald test. 
We next compared the relative excess risks of death estimated in children with those estimated in 
patients aged 15–19 years, 20–39 years, and 15–39 years. We assessed the significance of these 
differences using the Z test, assuming that differences in the logarithm of the relative excess risk of 
death had a normal distribution. We did the analyses with SEER*Stat (version 8.1.5), Microsoft 
Excel (version 2007), and Stata (version 13). 
Results	
Table 1 shows the numbers of cancers in AYAs, diagnosed in 2000–07, with main data quality 
indicators for both combined (adolescents and young adults) by country. 18 721 (6%) of 316 799 
cancers occurred in adolescents and 298 078 (94%) of 316 799 cancers occurred in young adults. 
Only 4316 (1·4%) of 316 799 cancers in AYAs were excluded: 1939 (0·6%) cancers because these 
were ascertained from death certificate or autopsy only; 1215 (0·4%) because these were censored 
immediately after diagnosis (had no follow-up); and 1162 (0·4%) because the records contained 
non-recoverable major errors (missing or invalid data items). 
Most cancers were microscopically verified (table 1). Scotland, Poland, and Croatia had the lowest 
proportions of microscopically verified cancers; for all other countries microscopic verification was 
93·9–99·6% (table 1). For 12 008 (3·8%) of 312 483 cancers, ICCC-3 morphology was unspecified. 
Croatia, Poland, and Latvia had the highest proportions of cancers with unspecified morphology; 
most (15) other countries had less than 3% unspecified morphology (table 1). Only 1991 (1·2%) of 
160 981 cancers diagnosed in 2000–03 were lost during follow-up. Switzerland had the greatest 
percentage of cancer cases loss to follow-up (9·7%), followed by Germany (3·0%), Poland (2·7%), 
Italy (2·3%), and France (2·2%; table 1). 
We estimated 5-year relative survival for 56 505 cancers diagnosed in children, 312 483 cancers in 
AYAs, and 3 567 383 cancers in adults. 5-year relative survival for all cancers combined was 76% 
(95% CI 75·3–76·8) for children, and 79% (78·9–79·3) for AYAs (appendix p 3), with no sex 
difference for children, but better survival for female compared with male AYAs (figure 1). Cancers 
with a good prognosis (Hodgkin's lymphoma, non-Hodgkin lymphoma, germ-cell tumours, 
melanoma, thyroid carcinoma, and breast carcinoma), were more frequent in AYAs (179 322 [57%] 
of 312 483 cancers) than in children (8305 [15%] of 56 505 cancers). Female AYAs had a slightly 
higher proportion of cancers with a good prognosis (eg, skin melanoma and thyroid cancer) than 
male AYAs (appendix p 4). Survival was better for female than male AYAs for acute myeloid 
leukaemias, Hodgkin's lymphoma, non-Hodgkin lymphoma, CNS neoplasms, soft-tissue sarcomas, 
melanoma, and thyroid carcinoma, breast carcinoma, head and neck carcinoma, lung carcinoma, 
and tracheal carcinoma (appendix p 4). 5-year relative survival was slightly better for male than for 
female AYAs with urinary tract carcinomas and gonadal germ-cell tumours. For the remaining 
cancer types (with at least 200 male cases and 200 female cases), no significant differences were 
found in 5-year relative survival between male and female AYAs (appendix p 4). 
Table 2 shows 5-year relative survival by 5-year age categories for the 19 non-carcinomas and 27 
carcinomas affecting AYAs. Haemopoietic malignancies were the most common cancers in the 15–
24 year age class, as in children. For all ages of AYAs, 5-year relative survival was greater than 
90% for Hodgkin's lymphoma, about 77% for non-Hodgkin lymphoma, and was relatively low for 
acute lymphoid leukaemias (46% to 62%) and acute myeloid leukaemias (about 50%). Gonadal 
germ-cell tumours and skin melanoma were the second and third most common cancers in AYAs; 
both had 5-year relative survival of 88% or higher in all age groups. 
Table 2. 5-year relative survival estimates for major cancers affecting European adolescents* and 
young adults† diagnosed in 2000–07 
15–19 years* 20–24 years† 25–29 years† 30–34 years† 35–39 years† 
  N 
Relative 
survival (SE) N 
Relative 
survival (SE) N 
Relative 
survival (SE) N 
Relative 
survival (SE) N 
Relative 
survival (SE)
Acute lymphoid leukaemia 1378 62·2% (1·6) 797 45·6% (2·0) 585 47·8% (2·4) 762 53·6% (2·1) 1095 60·5% (1·8) 
Acute myeloid leukaemia 704 52·2% (2·2) 819 55·2% (2·1) 1018 47·7% (1·8) 1104 49·3% (1·7) 1544 47·3% (1·5) 
Hodgkin's lymphomas 3541 94·3% (0·5) 4457 93·9% (0·4) 4164 93·9% (0·5) 3816 91·6% (0·6) 3300 90·2% (0·7) 
Non-Hodgkin lymphoma (excluding 
Burkitt's lymphoma) 1217 78·0% (1·4) 1667 76·3% (1·2) 2361 77·8% (1·0) 3762 78·0% (0·8) 6052 76·9% (0·7) 
CNS and miscellaneous intracranial and 
intraspinal neoplasms 1464 61·8% (1·5) 1804 63·4% (1·4) 2652 60·1% (1·1) 3774 57·4% (1·0) 4509 49·8% (0·9) 
Astrocytomas 604 50·8% (2·5) 850 54·2% (2·2) 1392 51·5% (1·7) 2056 47·6% (1·4) 2515 38·7% (1·2) 
 
Intracranial and intraspinal embryonal 
neoplasms 233 67·0% (3·8) 187 61·3% (4·3) 156 60·0% (4·2) 145 53·3% (4·9) 105 56·1% (6·0) 
Medulloblastomas 158 72·8% (4·5) 127 63·3% (4·8) 112 69·0% (5·3) 85 65·7% (5·7) 64 66·2% (7·0) 
Osteosarcomas 765 60·3% (2·2) 353 61·4% (3·2) 185 65·3% (4·0) 163 65·2% (4·7) 162 60·1% (4·4) 
Chondrosarcomas 140 80·7% (3·8) 134 80·5% (3·8) 162 85·5% (3·0) 245 82·7% (3·0) 313 83·1% (2·5) 
Ewing's sarcoma and related sarcomas 
of bone 448 51·1% (2·7) 241 50·4% (3·7) 136 45·3% (5·9) 112 47·7% (5·5) 75 42·9% (6·5) 
Soft-tissue and other extraosseous 
sarcomas (excluding Kaposi) 1185 63·0% (1·6) 1365 66·3% (1·5) 1699 68·5% (1·4) 2186 73·3% (1·1) 3062 72·2% (0·9) 
Rhabdomyosarcomas 280 39·6% (3·4) 155 35·8% (4·7) 84 30·9% (6·0) 74 39·0% (7·1) 83 43·2% (5·9) 
Fibrosarcomas 47 72·8% (9·8) 85 88·6% (3·6) 117 78·9% (5·0) 156 88·4% (3·0) 223 74·7% (3·7) 
Germ-cell tumours, trophoblastic 
tumours, and neoplasms of gonads 2238 92·2% (0·7) 5892 93·5% (0·4) 8991 95·2% (0·3) 9559 95·6% (0·3) 8885 94·7% (0·3) 
 
Intracranial and intraspinal germ-cell 
tumours 158 79·5% (4·2) 79 86·3% (5·1) 41 83·8% (6·2) 28 81·2% (6·2) 4 100% (0) 
Malignant gonadal germ-cell tumours 2011 93·6% (0·7) 5632 94·3% (0·4) 8715 95·9% (0·3) 9318 96·1% (0·3) 8684 95·4% (0·3) 
Malignant melanomas 1292 90·8% (1·2) 3772 90·9% (0·7) 6677 90·5% (0·5) 10 500 89·4% (0·5) 14 113 87·1% (0·4) 
Skin melanoma 1248 91·2% (1·2) 3669 91·2% (0·7) 6478 91·3% (0·5) 10 150 90·2% (0·5) 13 582 88·1% (0·4) 
Thyroid carcinomas 1063 99·7% (0·2) 2205 99·0% (0·3) 3778 99·3% (0·2) 5432 99·1% (0·2) 6918 98·9% (0·2) 
Breast carcinomas 53 87·3% (5·6) 550 82·9% (2·1) 3801 78·1% (0·9) 13 813 81·4% (0·4) 34 370 84·9% (0·3) 
Colorectal carcinomas (excluding 
carcinoids) 98 54·0% (6·5) 567 57·7% (2·5) 1220 57·0% (1·6) 2948 61·4% (0·9) 6524 62·4% (0·6) 
Appendix carcinoma (excluding 
carcinoids) 27 100·0% (0) 44 78·8% (2·6) 59 84·3% (4·6) 115 77·8% (5·2) 147 71·1% (5·1) 
Male genital tract carcinomas 21 83·8% (8·9) 85 88·0% (3·8) 126 80·8% (4·2) 161 76·7% (4·3) 418 77·9% (2·7) 
Testicular 16 82·6% (9·1) 76 89·2% (3·9) 77 87·9% (4·0) 64 85·5% (5·3) 58 87% (4·3) 
Penile 1 100·0% (0) 4 75·0% (21·7) 26 77·2% (9·3) 74 56·7% (6·3) 213 76·5% (4·0) 
Prostate 3 66·7% (27·2) 5 80·1% (17·9) 18 67·1% (16·6) 20 76·2% (10·4) 137 81·2% (5·1) 
Female genital tract carcinomas 197 80·5% (3·9) 1324 84·7% (1·4) 4781 83·3% (0·7) 9940 83·0% (0·5) 15 230 80·1% (0·4) 
Ovarian 154 81·1% (4·2) 423 81·8% (2·3) 836 76·5% (1·8) 1483 72·7% (1·4) 2869 69·9% (1·0) 
Uterine cervix 37 76·0% (10·0) 846 87·1% (1·6) 3735 84·8% (0·8) 7802 84·9% (0·5) 10 632 81·6% (0·4) 
 
Corpus uteri and uterine not otherwise 
specified 0 .. 28 81·0% (6·2) 117 89·3% (4·8) 428 91·9% (1·6) 1253 89·5% (1·1) 
Corpus uteri 0 .. 25 86·5% (6·0) 113 89·4% (4·8) 413 92·0% (1·6) 1218 89·2% (1·1) 
Urinary tract carcinomas 142 83·8% (3·4) 317 82·0% (2·5) 749 84·4% (1·6) 1752 84·6% (1·0) 3990 81·8% (0·7) 
Kidney 93 77·6% (4·8) 181 78·1% (3·2) 467 82·7% (2·1) 1099 85·8% (1·2) 2603 82·3% (0·8) 
Bladder 47 98·7% (1·3) 134 85·1% (4·9) 270 84·4% (3·1) 616 81·0% (1·9) 1284 79·9% (1·3) 
Head and neck carcinomas 340 84·4% (2·3) 488 81·1% (2·1) 804 81·3% (1·6) 1610 73·9% (1·4) 3691 63·8% (0·9) 
Nasal cavity and sinuses 8 NE 20 59·9% (8·7) 41 56·5% (9·2) 119 62·6% (5·1) 196 59·0% (4·2) 
Nasopharynx 129 74·5% (5·3) 127 76·3% (4·5) 124 71·3% (4·7) 199 66·5% (3·9) 368 68·1% (2·7) 
Salivary gland 119 94·0% (2·9) 153 93·5% (2·3) 240 92·3% (2·2) 323 87·0% (2·5) 468 83·0% (2·2) 
Hypopharynx 1 100·0% (0) 1 NE 8 29·3% (0) 26 46·5% (10·7) 159 31·3% (3·9) 
Larynx 10 100·0% (0) 16 93·4% (6·4) 44 89·5% (5·5) 131 72·6% (4·6) 530 71·3% (2·2) 
15–19 years* 20–24 years† 25–29 years† 30–34 years† 35–39 years† 
  N 
Relative 
survival (SE) N 
Relative 
survival (SE) N 
Relative 
survival (SE) N 
Relative 
survival (SE) N 
Relative 
survival (SE)
Oropharynx carcinoma 15 93·4% (6·4) 32 74·2% (7·7) 74 78·5% (6·7) 180 70·0% (4·2) 684 50·5% (2·1) 
Oral cavity carcinoma 48 87·0% (4·0) 120 74·0% (4·5) 239 77·6% (3·4) 537 71·3% (2·4) 1097 61·6% (1·8) 
Lip carcinoma 6 66·7% (19·2) 12 74·4% (18·3) 27 98·9% (1·0) 71 95·4% (2·0) 153 93·7% (2·1) 
Liver and intrahepatic bile duct 
carcinomas 95 16·0% (5·2) 119 31·4% (5·6) 175 35·5% (4·4) 344 21·1% (2·6) 564 26·1% (2·3) 
Lung and trachea carcinomas 103 87·1% (4·1) 208 71·4% (3·5) 462 54·2% (2·7) 1112 38·9% (1·6) 3552 23·5% (0·8) 
Survival figures are population weighted. NE=not estimable. SE=standard error of the relative 
survival ratio. 
* 
Adolescents (aged 15–19 years). 
† 
Young adults (aged 20–39 years). 
 
For CNS neoplasms, 5-year relative survival was about 60% in patients aged up to 29 years, and 
was lower in older age classes, especially for astrocytomas (to around 41%). Osteosarcoma and 
Ewing's sarcoma were the most common bone sarcomas in adolescents (aged 15–19 years) and 
those aged 20–24 years, whereas chondrosarcomas, as a proportion of all bone sarcomas, increased 
progressively in those from ages 20–24 years and older. 5-year relative survival was good for 
osteosarcoma and chondrosarcoma. For Ewing's sarcoma 5-year relative survival reduction across 
age categories was not significant (p=0·24), whereas for soft-tissue sarcomas, 5-year relative 
survival significantly increased across age catgeories (p<0·0001). 
Carcinomas were rarely diagnosed in AYAs, but occurrence increased with advancing age from 25–
29 years and older (table 2). In adolescents, thyroid carcinoma was the most common carcinoma 
and had excellent 5-year relative survival (99·7%). Head and neck carcinomas (mainly at 
nasopharyngeal and salivary gland sites) were the second most common carcinomas in adolescents, 
followed by colorectal and ovarian carcinomas (all with good or fairly good survival). For most 
other carcinomas in adolescents, 5-year relative survival was greater than 75% (except for liver 
carcinoma at <20%). 
In young adults, female genital tract and breast carcinomas were the most common malignancies, 
with 5-year relative survival about 80% in all age classes (table 2); cervical carcinoma was the most 
common female genital tract carcinoma, with high 5-year relative survival in all age groups. Other 
relatively common carcinomas in young adults were thyroid and colorectal carcinomas, with 
excellent (99%) 5-year relative survival for thyroid, and intermediate (about 60%) relative survival 
for colorectal carcinomas (excluding carcinoids). 5-year relative survival for male genital and head 
and neck carcinomas declined with with advancing age as the site of occurrence changed (table 2). 
5-year relative survival declined substantially with age for carcinomas of the lung and trachea (table 
2), in relation to an age-related decline in the proportion of well differentiated carcinoids (73% in 
adolescents; 13% in those aged 35–39 years). 5-year relative survival for liver carcinomas was poor 
for all AYA age categories. 
Table 3 compares 5-year relative survival in children with that in adolescents, young adults, and 
AYAs, for the 19 diagnostic cancers categories affecting children and AYAs (appendix p 1). AYAs 
had significantly worse survival than children for acute lymphoid leukaemias, acute myeloid 
leukaemias, Hodgkin's lymphoma, non-Hodgkin lymphoma, astrocytomas, Ewing's sarcoma of 
bone, rhabdomyosarcoma, and osteosarcoma (table 3). AYAs had significantly better survival than 
children for medulloblastomas and germ-cell tumours. Survival differences between children and 
adolescents, and children and young adults, were similar to the differences between children and 
AYAs for most cancers in table 3. 
Table 3. 5-year relative survival in European children in comparison to survival in adolescents, 
young adults, and AYAs for major cancers affecting children and AYAs diagnosed in 2000–07 
  
Children (0–14 
years) Adolescents (15–19 years) Young adults (20–39 years) AYAs (15–39 years) 
  N 
Relative 
survival 
(SE) 
N 
Relative 
survival 
(SE) 
p value* N 
Relative 
survival 
(SE) 
p value* N 
Relative 
survival 
(SE) 
p value*
Acute lymphoid leukaemias 15 089 85·8% (0·4) 1378 62·2% (1·6) <0·0001 3239 52·8% (0·01) <0·0001 4617 55·6% (0·9) <0·0001
Acute myeloid leukaemias 2944 60·5% (1·0) 704 52·2% (2·2) 0·0007 4484 49·4% (0·9) <0·0001 5188 49·8% (0·8) <0·0001
Hodgkin's lymphomas 2995 95·1% (0·5) 3541 94·3% (0·5) 0·21 15 735 92·6% (0·3) <0·0001 19 276 92·9% (0·2) <0·0001
Non-Hodgkin lymphomas 
(excluding Burkitt's lymphoma) 2407 83·0% (0·9) 1217 78·0% (1·4) 0·0023 13 840 77·3% (0·4) <0·0001 15 057 77·4% (0·4) <0·0001
CNS and miscellaneous intracranial 
or intraspinal neoplasms 8856 57·2% (0·6) 1464 61·8% (1·5) 0·0090 12 722 56·1% (0·5) 0·15 14 184 56·8% (0·5) 0·52 
Astrocytomas 2584 61·9% (1·1) 604 50·8% (2·5) 0·0003 6803 46·0% (0·7) <0·0001 7405 46·4% (0·7) <0·0001
 
Intracranial and intraspinal 
embryonal neoplasms 2951 56·3% (1·1) 233 67·0% (3·8) 0·0074 593 57·8% (2·4) 0·51 826 60·3% (2·0) 0·074 
Medulloblastomas 2156 63·2% (1·3) 158 72·8% (4·5) 0·041 388 67·4% (2·8) 0·15 546 69·3% (2·3) 0·020 
Osteosarcoma 1430 66·8% (1·5) 765 60·3% (2·2) 0·012 863 62·5% (1·9) 0·070 1627 61·5% (1·5) 0·011 
Chondrosarcoma 66 89·4% (3·4) 140 80·7% (3·8) 0·092 854 83·0% (1·5) 0·084 994 82·6% (1·4) 0·064 
Ewing's sarcoma and related 
sarcomas of bone 1322 66·6% (1·5) 448 51·1% (2·7) <0·0001 564 47·4% (2·5) <0·0001 1012 49·3% (1·8) <0·0001
Soft-tissue and other extraosseous 
sarcomas (excluding Kaposi) 3871 69·3% (0·9) 1185 63·0% (1·6) 0·0007 8310 70·8% (0·6) 0·19 9493 69·8% (0·5) 0·66 
Rhabdomyosarcomas 2124 66·6% (1·3) 280 39·6% (3·4) <0·0001 396 36·4% (2·8) <0·0001 675 37·8% (2·2) <0·0001
Fibrosarcomas 209 83·8% (3·6) 47 72·8% (9·8) 0·29 581 81·5% (2·0) 0·60 628 81·4% (1·9) 0·56 
Germ-cell tumours, trophoblastic 
tumours, and neoplasms of gonads 1805 91·5% (0·8) 2238 92·2% (0·7) 0·55 33 272 94·9% (0·2) <0·0001 35 503 94·7% (0·1) 0·00013
 
Intracranial and intraspinal germ-
cell tumours 466 85·9% (2·2) 158 79·5% (4·2) 0·18 152 79·0 %(4·2) 0·13 310 79·5% (2·9) 0·077 
 
Malignant gonadal germ-cell 
tumours 821 96·8% (0·8) 2011 93·6% (0·7) 0·0015 32 295 95·6% (0·2) 0·11 34 300 95·4% (0·1) 0·078 
Malignant melanomas 435 90·1% (1·7) 1292 90·8% (1·2) 0·70 34 994 88·9% (0·3) 0·47 36 279 88·9% (0·3) 0·50 
Skin melanoma 394 92·2% (1·6) 1248 91·2% (1·2) 0·64 33 814 89·7% (0·3) 0·14 35 055 89·7% (0·3) 0·15 
 
Relative survival data are population weighted. AYAs=adolescents and young adults. SE=standard 
error of the relative survival ratio. 
* 
For comparison with children (aged 0–14 years). 
 
Table 4 compares 5-year relative survival in AYAs with that in adults for the 27 carcinomas 
affecting both age groups. For most carcinomas, survival was better for AYAs than for adults, with 
some notable exceptions such as colorectal, breast, and prostate carcinomas. 5-year survival for 
colorectal cancer was similar for AYAs and adults; for both breast and prostate carcinoma survival 
was significantly lower for AYAs than adults (table 4). 
Table 4. 5-year relative survival in European AYAs in comparison with survival in adults for major 
carcinomas affecting AYAs and adults for cases diagnosed in 2000–07 
  AYAs (15–39 years) Adults (40–69 years) 
p value (15–39 years vs 40–69 
years) 
  N 
Relative survival 
(SE) N 
Relative survival 
(SE)  
Malignant melanomas 36 279 88·9% (0·3) 104 019 82·4% (0·2) <0·0001 
Thyroid carcinomas 19 396 99·2% (0·1) 45 834 93·1% (0·2) <0·0001 
Breast carcinomas 52 468 83·5% (0·2) 658 113 87·0% (0·1) <0·0001 
Colorectal carcinomas (excluding carcinoids) 11 344 61·3% (0·5) 395 525 60·8% (0·1) 0·49 
Appendix carcinoma (excluding carcinoids) 392 77·2% (3·7) 2273 61·0% (1·5) 0·0001 
Male genital tract carcinomas 811 80·1% (1·8) 406 036 89·6% (0·1) <0·0001 
Testicular 291 87·5% (2·3) 220 72·3% (3·6) 0·00034 
Penile 318 72·8% (3·8) 5327 70·5% (0·9) 0·55 
Prostate 183 79·9% (4·0) 400 311 89·8% (0·1) 0·014 
Female genital tract carcinomas 31 460 81·6% (0·3) 237 360 69·1% (0·1) <0·0001 
Ovarian 5763 72·8% (0·7) 75 605 47·1% (0·2) <0·0001 
Cervix uteri 23 050 83·3% (0·3) 50 536 67·7% (0·3) <0·0001 
 
Corpus uteri and uterus not otherwise 
specified 1826 90·0% (0·9) 101 293 86·7% (0·2) 0·00025 
Corpus uteri 1769 89·9% (0·9) 100 017 87·0% (0·2) 0·00073 
Urinary tract carcinomas 6942 82·9% (0·9) 206 536 69·5% (0·1) <0·0001 
Kidney 4437 83·0% (0·6) 92 194 70·7% (0·2) <0·0001 
Bladder 2351 81·4% (1·0) 106 194 69·1% (0·2) <0·0001 
Head and neck carcinomas 6929 69·9% (0·6) 166 146 51·5% (0·1) <0·0001 
Nasal cavity and sinuses 383 60·2% (3·0) 4854 53·0% (0·9) 0·021 
Nasopharynx 947 69·9% (1·7) 4839 51·2% (0·9) <0·0001 
Salivary gland 1303 88·2% (1·1) 6861 64·4% (0·7) <0·0001 
Hypopharynx 195 34·3% (3·6) 15 631 26·2% (0·4) 0·024 
Larynx 731 72·9% (1·8) 48 857 61·8% (0·3) <0·0001 
Oropharynx 985 57·5% (1·8) 39 354 42·0% (0·3) <0·0001 
Oral cavity 2041 66·7% (1·3) 37 749 48·3% (0·3) <0·0001 
Lip 268 92·2% (2·2) 6863 90·2% (0·6) 0·37 
Liver and intrahepatic bile duct carcinomas 1297 25·2% (1·4) 36 887 14·2% (0·2) <0·0001 
Lung and trachea carcinomas 5437 32·1% (0·7) 379 762 14·9% (0·1) <0·0001 
Survival figures are population weighted. AYAs=adolescents and young adults. SE=standard error 
of the relative survival ratio. 
5-year relative survival for all cancers combined increased significantly from 76% (95% CI 74·7–
77·1) in 1999–2001, to 79% (77·2–79·4) in 2005–07 for children (p<0·0001); from 77% (77·2–
79·4) to 80% (78·8–82·2) for adolescents (p<0·0001); and from 79% (78·2–80·7) to 83% (81·1–
84·0) for young adults (p<0·0001), and from 79% (78·1–80·5) to 82% (81·1–83·3) for AYAs 
(p<0·0001; figure 2). 5-year relative survival improved significantly with time in all age groups for 
acute lymphoid leukaemias and non-Hodgkin lymphomas. 5-year relative survival improved 
significantly only in children for acute myeloid leukaemias, soft-tissue sarcoma, and fibrosarcoma. 
Survival improved significantly only in young adults for CNS tumours, astrocytomas, and 
melanoma (figure 2). For the all other diagnostic categories and all age classes, survival remained 
stable over the study period. 
We found that relative excess risks of death differed between age groups for several cancers. For 
acute lymphoid leukaemias, relative excess risk of death reduced significantly more in adolescents 
than in children (p=0·015). For CNS tumours in general, relative excess risk of death reduced 
significantly more in young adults than in children (p=0·037); and for astrocytomas relative excess 
risk of death reduced significantly more in young adults than in children (p=0·0047). For 
fibrosarcomas, relative excess risk of death reduced significantly more in children than in AYAs 
(p=0·015). For all other diagnostic categories with significant changes in survival over time, no 
significant differences in relative excess risk of death between children and AYAs were found 
(appendix p 5). 
Discussion	
Two major findings of our study were that survival improved over time (1999–2007) for both 
AYAs and children with cancer in Europe, and that the level of improvement was similar in both 
groups. Thus, the slower survival improvement reported by Bleyer and colleagues,2 up to the 1990s 
for AYAs in the USA compared with children, seems not to be present in Europeans diagnosed 
more recently. 
Another major finding of our study was that, overall, AYAs had slightly better 5-year relative 
survival than children (figure 1), mainly because cancers with good prognoses were more frequent 
in AYAs than in children. In fact survival in AYAs lagged behind that in children for several 
cancers that affect both groups, particularly for relatively common haemopoietic malignancies. 
Thus, 5-year relative survival was significantly worse in AYAs than in children for acute lymphoid 
leukaemias, acute myeloid leukaemias, Hodgkin's lymphoma, non-Hodgkin lymphoma, 
astrocytoma, Ewing's sarcoma of bone, rhabdomyosarcoma, and osteosarcoma (table 3). 
Furthermore, for acute myeloid leukaemias, soft-tissue sarcoma, and fibrosarcoma, survival 
remained unchanged for AYAs over the study period. These findings are consistent with data from 
earlier periods1, 2 and justify initiatives to improve cancer outcomes for AYAs in Europe.8 
For cancers in AYAs that also affect children, it has been suggested that AYAs should be treated in 
an integrated paediatric–adult multidisciplinary setting.8 This change should increase the likelihood 
of AYAs being included in clinical trials, and improve family and social support.8 For acute 
lymphoid leukaemias, data clearly indicate that although tumour biology is relatively unfavourable 
in AYAs, application of treatment protocols for children is feasible and improves outcomes.20, 21, 
22, 23 
Of note, survival for acute lymphoid leukaemias in AYAs improved substantially over the study 
period (1999–2007), particularly in those aged 15–19 years (figure 2). By 2005–07, 5-year relative 
survival for acute lymphoid leukaemias had reached nearly 60%, compared with 50% for acute 
myeloid leukaemias. This is an important change since, in the previous EUROCARE period (1995–
2002), survival of AYAs was worse for those with acute lymphoid leukaemias than acute myeloid 
leukaemias.1 This improved survival for AYAs with acute lymphoid leukaemias probably reflects 
increasing use of paediatric treatment protocols in this older age group. Imatinib (plus 
chemotherapy) is indicated for adults and children with newly diagnosed Philadelphia chromosome-
positive acute lymphoid leukaemia; thus increasing use of imatinib in AYAs with this form of 
leukaemia could have contributed to the improvement. However only a small percentage (3–11%) 
of AYAs with acute lymphoid leukaemias have this translocation.24 Furthermore, treatment-related 
information was not systematically available from cancer registries and could not be analysed in 
this study. In general, whether chemotherapy regimens for children are appropriate for AYAs older 
than 20 years is unclear.25 
In addition to advocating the development of integrated child and adult multidisciplinary models of 
care, greater inclusion in clinical trials, and research to improve treatments, the European Network 
for Teenagers and Young Adults with Cancer (created in the context of the ENCCA) is promoting 
the development of AYA-specific practice guidelines, education for cancer care, healthy lifestyles, 
and greater involvement of patients and patient support organisations.8 
We also found that female AYAs had better survival than male AYAs (figure 1), mainly for acute 
myeloid leukaemias, Hodgkin's lymphoma, non-Hodgkin lymphoma, CNS neoplasms, soft-tissue 
sarcomas, and melanoma. Sex differences in adult cancer survival have been reported previously26 
with sex hormones proposed as the prime mediators of the survival advantage in women. Whether 
this explanation is applicable to AYAs is unclear and merits further study. 
We found that AYAs had better survival for most cancers (carcinomas) that affect AYAs and 
adults, supporting the idea that young patients with few comorbidities are likely to do better than 
older patients. However, tumour biology (including gene expression alterations), histotype, and 
stage at diagnosis are also likely to influence survival in AYAs. Furthermore, casemix was more 
favourable in AYAs than adults for female genital tract cancers (cervix uteri: 23 050 [73%] of 
31 460 cancers vs 50 536 [21%] of 237 360 cancers) and head and neck cancers (salivary gland 
cancer: 1303 [19%] of 6929 cancers vs 6861 [4%] of 166 146 cancers). 
However, AYAs had worse survival than adults for breast and prostate carcinomas. For breast 
cancer, this might be because, compared with older women, young women present with larger, less 
hormone-sensitive, higher grade cancers, that have often spread to lymph nodes.27, 28 For prostate 
cancer, older men have biologically less aggressive disease than younger men. Additionally, 
because older men usually die sooner after diagnosis (due to causes unrelated to prostate cancer) 
compared with younger men, they are less likely to experience disease progression or develop 
treatment-related morbidities.29, 30 
We do not present 1-year relative survival in this study; because of the good prognosis of most 
cancers we analysed, and the long life expectancy of the young population, 5-year relative survival 
was judged a good summary measure of cancer outcomes in AYAs. An improvement in 1-year 
relative survival not confirmed in 5-year relative survival might indicate aggressive early treatment 
that did not improve long-term outcomes and in this study we were mainly interested in 
documenting real gains in AYA survival. 
In our database, coverage by country was quite variable. However, we present European survival 
estimates that are less likely, than country comparisons, to be biased by inadequate representativity 
of data for some countries. 
Two age definitions of AYAs (15–24 years and 15–29 years) are widely used in the scientific 
literature. We used the age 15–39 years definition proposed by the National Cancer Institute10 and 
endorsed by the ENCCA, based on the reasoning that this age category has had relatively little 
improvement in survival, and a major concern for AYAs with cancer is that they do not have a 
“home” in research and health care.10 
In the absence of an updated classification of cancers occurring in AYAs,31 we used an ad-hoc 
classification into 46 diagnostic categories based on cancer morphology and site. 
A strength of our study was that we evaluated outcomes in a large population-based database of 
child, AYA, and adult cancer cases archived by European cancer registries. In the future, data 
provided by these registries will be vital to assess whether changes in management policies have the 
desired effect to improve survival in European AYAs who develop cancer. 
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